Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: A propensity score analysis

Critical Care Medicine

Volumn 35, Issue 7, 2007, Pages 1685-1690

  Tritapepe, Luigi ^a   De Santis, Vincenzo ^a,e   Vitale, Domenico ^a   Nencini, Cecilia ^b   Pellegrini, Fabio ^c   Landoni, Giovanni ^d   Toscano, Federico ^a   Miraldi, Fabio ^a   Pietropaoli, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c Consorzio Mario Negri Sud ^*  (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Dipto di Sci Clin (Endocrinol)   (Italy)

Author keywords

Bleeding; Cardiac surgery; Hemostasis; Recombinant activated factor VII; Thromboembolism; Transfusion

Indexed keywords

ANTITHROMBIN; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADULT; AGED; AORTA DISSECTION; AORTA SURGERY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARREST; HEART INFARCTION; HUMAN; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER DYSFUNCTION; MALE; OPERATING ROOM; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SCORING SYSTEM; STROKE; THROMBOPLASTIN TIME;

EID: 34250901460     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000269033.89428.B3     Document Type: Article

References (33)

1. Hagan PG, Nienaber CA, Isselbacher EM, et al: The International Registry of Acute Aortic Dissection (IRAD): New insights into an old disease. JAMA 2000; 283:897-903
2. Wilde JT: Hematological consequences of profound hypothermic circulatory arrest and aortic dissection. J Card Surg 1997; 12(Suppl):201-206
3. Woodman RC, Harker LA: Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76:1680-1697
4. Ten Cate JW, Timmers H, Becker AE: Coagulopathy in ruptured or dissecting aortic aneurysm. Am J Med 1975; 59:171-176
5. Hedner U, Ingerslev J: Clinical use of recombinant factor VIIa (rVIIa). Transfus Sci 1998; 19:163-176
6. von Heymann C, Kastrup M, Redlich U, et al: Experiences with recombinant activated factor VII (rFVIIa) for refractory bleeding after cardiac surgery. Anesthesiology 2003; 99:A-442
7. Karkouti K, Wijeysundera DN, McCluskey SA, et al: Efficacy and safety of recombinant factor VIIa (rF-VIIa) for treating refractory blood loss after cardiac surgery. Anesthesiology 2003; 99:A-164
8. O'Connell NM, Perry DJ, Hodgson AJ, et al: Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43:1711-1716
9. Diprose P, Herbertson MJ, O'Shaughnessy D, et al: Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95:596-602
10. Karkouti K, Beattie WS, Wijeysundera DN, et al: Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensity score-matched case-control analysis. Transfusion 2005; 45:26-34
11. von Heymann C, Redlich U, Jain U, et al: Recombinant activated factor VII for refractory bleeding after cardiac surgery - A retrospective analysis of safety and efficacy. Crit Care Med 2005; 33:2241-2246
12. O'Connell KA, Wood JJ, Wise RP, et al: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298
13. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-2281
14. Yanovitzky I, Zanutto E, Hornik R: Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 2005; 28:209-220
15. Parsons LS: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference. Cary, NC, SAS Institute, 2004
16. Lin DY, Psaty BM, Krommal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54:948-963
17. Nuttall GA, Oliver WC, Ereth MH, et al: Comparison of blood conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 2000; 92:674-682
18. Wiesenack C, Arlt M, Liebold A, et al: Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2004; 128:941-943
19. Stratmann G, Russell IA, Merrick SH: Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg 2003; 76:2094-2097
20. Hyllner M, Houltz E, Jeppsson A: Recombinant activated factor VII in the management of lifethreatening bleeding in cardiac surgery. Eur J Cardiothorac Surg 2005; 28:254-258
21. Romagnoli S, Bevilacqua S, Gelsomino S, et al: Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102:1320-1326
22. Harker LA: Bleeding after cardiopulmonary bypass. N Engl J Med 1986; 314:1446-1447
23. Kestin AS, Valeri CR, Khuri SF, et al: The platelet function defect of cardiopulmonary bypass. Blood 1993; 82:107-117
24. Valeri CR, Feingold H, Cassidy G, et al: Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987; 205:175-181
25. ten Cate JW, Timmers H, Becker AE: Coagulopathy in ruptured or dissecting aortic aneurysms. Am J Med 1975; 59:171-176
26. Karthik S, Grayson AD, McCarron EE, et al: Reexploration for bleeding after coronary artery bypass surgery: Risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 2004; 78:527-534
27. Ghorashian S, Hunt BJ: "Off-license" use of recombinant activated factor VII. Blood Rev 2004; 18:245-259
28. Moons AH, Levi M, Peters RJ: Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53:313-325
29. Dietrich W, Spannagl M: Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002; 94:1369-1371
30. Chung JH, Gikakis N, Rao AK, et al: Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93:2014-2018
31. Ernofsson M, Thelin S, Siegbahn A: Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: A clinical study. J Thorac Cardiovasc Surg 1997; 113:576-584
32. Hoffman M, Monroe DM, Roberts HR: Activated factor VII activates factors IX and X on the surface of the activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1988; 9(Suppl 1):S61-S65
33. Karkouti K, Yau TM, Riazi S, et al: Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 2006; 53:802-809